Related Experiment Video

Updated: Sep 9, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Non-coding RNAs-glycolysis axis in cancer therapy resistance: Insight into mechanism to therapeutic solution

Jiachen Tan1, Qinzheng Xu2, Nuruliarizki Shinta Pandupuspitasari3

  • 1School of Medicine, Nantong University, Nantong 226001, China.

Biochemical Pharmacology
|September 3, 2025
PubMed

Insights

Cancer cells resist treatment by altering glycolysis, a process regulated by signaling molecules and non-coding RNAs (ncRNAs). Herbal medicine can overcome this resistance by targeting the ncRNA-glycolysis axis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer therapy resistance is a major clinical hurdle, often linked to metabolic reprogramming, specifically dysfunctional glycolysis in cancer cells.
  • Key signaling molecules (EGFR, HIF-1α, AMPK, β-catenin) and non-coding RNAs (ncRNAs) like miRNAs, lncRNAs, and circRNAs are implicated in regulating glycolysis and mediating treatment resistance.

Purpose of the Study:

  • To review the role of ncRNAs and their regulatory networks in cancer glycolysis and drug resistance.
  • To explore the potential of targeting the ncRNA-glycolysis axis to overcome cancer therapy resistance.

Main Methods:

  • Literature review focusing on studies investigating ncRNAs, glycolysis, and cancer drug resistance.
  • Analysis of regulatory mechanisms including competitive endogenous RNA (ceRNA) networks and exosomal ncRNAs.
  • Examination of the impact of herbal medicine on the ncRNA-glycolysis axis in cancer.

Main Results:

  • ncRNAs, including miRNAs, lncRNAs, and circRNAs, significantly modulate cancer glycolysis and drug resistance.
  • ceRNA networks (circRNA/lncRNA-miRNA-mRNA) and exosomal ncRNAs are crucial in regulating glycolytic pathways and mediating resistance.
  • Certain miRNAs can either inhibit or promote glycolysis, influencing therapy outcomes.

Conclusions:

  • The ncRNA-glycolysis axis is a critical determinant of cancer therapy resistance.
  • Targeting this axis, potentially through herbal medicine, offers a promising strategy to overcome drug resistance in cancer.
Keywords:
Cancer therapy resistanceGlycolysisHerbal medicineNon-coding RNAsTumor microenvironment

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

634

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K